Both hamster and the LDLr-/- mice showed efficacy in terms of slowing down atherosclerosis progression without modulating circulating proatherogenic lipoproteins, suggesting that the reductions in lesion area was not due to proatherogenic lipoproteins, but other mechanism(s). The gene discussed is LDLR; the disease is atherosclerosis.